Traders sold shares of Edwards Lifesciences Corp. (NYSE:EW) on strength during trading hours on Friday. $115.23 million flowed into the stock on the tick-up and $134.70 million flowed out of the stock on the tick-down, for a money net flow of $19.47 million out of the stock. Of all companies tracked, Edwards Lifesciences Corp. had the 0th highest net out-flow for the day. Edwards Lifesciences Corp. traded up $3.12 for the day and closed at $118.07

Several equities research analysts have issued reports on the company. Canaccord Genuity reaffirmed a “buy” rating and set a $140.00 price target on shares of Edwards Lifesciences Corp. in a research note on Thursday. Evercore ISI reaffirmed a “hold” rating and set a $115.00 price target on shares of Edwards Lifesciences Corp. in a research note on Friday. Credit Suisse Group AG set a $116.00 target price on Edwards Lifesciences Corp. and gave the company a “buy” rating in a research note on Thursday. Morgan Stanley reissued a “buy” rating and issued a $140.00 target price on shares of Edwards Lifesciences Corp. in a research note on Friday. Finally, Leerink Swann reissued a “buy” rating on shares of Edwards Lifesciences Corp. in a research note on Friday. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have assigned a buy rating to the stock. Edwards Lifesciences Corp. presently has an average rating of “Buy” and a consensus price target of $118.13.

The stock has a market cap of $25.13 billion and a PE ratio of 48.79. The firm’s 50-day moving average is $109.57 and its 200-day moving average is $99.30.

Edwards Lifesciences Corp. (NYSE:EW) last posted its quarterly earnings results on Tuesday, July 26th. The medical research company reported $0.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.70 by $0.06. The company had revenue of $759.30 million for the quarter, compared to the consensus estimate of $724.26 million. The business’s revenue was up 23.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.57 EPS. Equities analysts predict that Edwards Lifesciences Corp. will post $2.87 earnings per share for the current fiscal year.

In related news, Director Schack Wesley W. Von sold 6,000 shares of Edwards Lifesciences Corp. stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $113.98, for a total transaction of $683,880.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Steven R. Loranger acquired 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 24th. The shares were acquired at an average cost of $101.07 per share, for a total transaction of $505,350.00. Following the completion of the acquisition, the director now owns 1,941 shares of the company’s stock, valued at $196,176.87. The disclosure for this purchase can be found here.

A number of institutional investors have modified their holdings of EW. RS Investment Management Co. LLC raised its position in shares of Edwards Lifesciences Corp. by 77.6% in the fourth quarter. RS Investment Management Co. LLC now owns 168,325 shares of the medical research company’s stock valued at $13,294,000 after buying an additional 73,540 shares during the last quarter. BlackRock Advisors LLC raised its position in shares of Edwards Lifesciences Corp. by 117.5% in the fourth quarter. BlackRock Advisors LLC now owns 1,169,922 shares of the medical research company’s stock valued at $92,400,000 after buying an additional 631,958 shares during the last quarter. Utah Retirement Systems raised its position in shares of Edwards Lifesciences Corp. by 99.0% in the fourth quarter. Utah Retirement Systems now owns 38,536 shares of the medical research company’s stock valued at $3,044,000 after buying an additional 19,168 shares during the last quarter. KBC Group NV raised its position in shares of Edwards Lifesciences Corp. by 279.9% in the fourth quarter. KBC Group NV now owns 130,931 shares of the medical research company’s stock valued at $10,341,000 after buying an additional 96,462 shares during the last quarter. Finally, State of Tennessee Treasury Department raised its position in shares of Edwards Lifesciences Corp. by 47.3% in the fourth quarter. State of Tennessee Treasury Department now owns 90,877 shares of the medical research company’s stock valued at $7,178,000 after buying an additional 29,177 shares during the last quarter.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.